米氮平合并氨磺必利或喹硫平治疗难治性抑郁症的对照研究

A control study of mirtazapine combined with amisulpride /quetiapine on the treatment of refractory depression

目的探讨米氮平联合氨磺必利、喹硫平治疗难治性抑郁症的疗效和安全性。方法将84例难治性抑郁症患者随机分为氨磺必利组(米氮平联合氨磺必利组)和喹硫平组(米氮平联合喹硫平),治疗观察6周,采用汉密尔顿抑郁量表(HAMD-17)和副反应量表(TESS)评定疗效及不良反应。结果氨磺必利组显效率为69.04%,喹硫平组为71.43%,均显示出较好的疗效,两组显效率的差异无统计学意义(χ2=0.057,P>0.05),氨磺必利组起效快于喹硫平组,两组不良反应均较少,喹硫平组嗜睡副作用明显多于氨磺必利组。结论米氮平联合氨磺必利、喹硫平治疗难治性抑郁症疗效均较好,不良反应均较轻微,喹硫平组嗜睡副作用稍多,氨磺必利组起效较快。

Objective To investigatethe efficacy and safety of mirtazapinecombined with amisnlpride/ quetiapine on the treatment of refractory depression. Methods Patients （ n = 84 ） with treatment-resistant depression were divided into amisulpride group （mirtazapine eombinedamisulpride ） and quetiapine group （mirtazapine combined quetiapine） randomly, the treatment last for 8 weeks, employing the Hamilton Depression Rating Scale （HAMD） and adverse reactions scale （TESS） to evaluate the efficacy and adverse reactions. Results Effective rate of Amisulpridegroup was 69.04% , and it was 71.43% for quetiapine group, but the differences of significant efficiency between the two groupspresent no statistically significant（ Х^2 = 0. 057, P 〉 0. 05 ）, amisulpridegroup present effective more rapidlythan quetiapine group, and few adverse reactions wereobserved. But there were more patients in quetiapine group present drowsiness than amisulpride group. Conclusions Mirtazapine combined with amisulpride/quetiapine were effecttive for the treatment of refractory depression, adverse reactions for both group were mild, side effects of drowsiness in quetiapine group were less than that in amisulpride group, amisulpride group present effective more rapidly than quetiapine group.